PR Newswire
NEW YORK, Dec. 20, 2024
NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Kyverna and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until February 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired DMC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On or around February 8, 2024, Kyverna conducted its initial public offering ("IPO"), offering 14.5 million shares of common stock at a price of $22.00 per share.
Then, on June 14, 2024, Kyverna hosted an industry symposium at the European Alliance of Associations for Rheumatology in Vienna and provided an update on KYV-101, its lead product candidate.
That same day, the Company published an investor presentation that disclosed adverse data regarding one of its clinical trials. Following these disclosures, Kyverna's stock price fell $4.91 per share, or 34%, to close at $9.53 per share on June 14, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-kyverna-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--kytx-302337656.html
SOURCE Pomerantz LLP
